Popa S A, Bucătariu P M, Azoicăhi Doina, Costin D, Manole Alina, Matei Mioara, Merchez Mihaela
Universităţii de Medicină şi Farmacie Gr. T. Popa Iaşi Universitatea de Medicină şi Farmacie Gr. T. Popa Iaşi Facultatea de Medicină.
Rev Med Chir Soc Med Nat Iasi. 2011 Apr-Jun;115(2):455-9.
The authors present some observations regarding the use of topical anti-glaucoma therapy and systemic vasodilators.
The study was carried out on a series of 996 glaucoma patients, of which 54.1% with primary open-angle glaucoma, 5.7% closed-angle glaucoma, and 17.6% with normal intraocular pressure.
Intraocular pressure and visual field were assessed after the use of such therapeutic methods as carbonic anhydrase inhibitors (dorzolamide) and prostaglandin (latanoprost) and dorzolamide (cosopt) association.
The favorable progression of glaucoma could be improved by using new etiopathogenic mechanisms and treatment approaches.
作者介绍了一些关于局部抗青光眼治疗和全身血管扩张剂使用的观察结果。
对996例青光眼患者进行了研究，其中原发性开角型青光眼患者占54.1%，闭角型青光眼患者占5.7%，眼压正常者占17.6%。
使用碳酸酐酶抑制剂（多佐胺）、前列腺素（拉坦前列素）和多佐胺（可速比妥）联合等治疗方法后，评估了眼压和视野。
通过采用新的病因发病机制和治疗方法，可改善青光眼的良好进展。
